Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2018-07-24 Interim / Quarterly Rep…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It provides financial results for the quarter ended June 30, 2018, including detailed financial data such as consolidated statements of financial position and comprehensive income. The document includes management commentary on financial performance and operational updates. The presence of actual financial statements and substantive financial data for a half-year period indicates this is an interim or quarterly report rather than a mere announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2018-07-24 English
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filing by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains detailed financial results for the quarter ended March 31, 2018, including consolidated statements of financial position and comprehensive income, as well as management commentary on financial performance and business updates. The presence of actual financial data and analysis for a quarterly period indicates this is an Interim / Quarterly Report. The document is not merely an announcement or a certification but includes substantive financial statements and discussion. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2018-05-29 English
Immediate Report
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. It contains the company's financial results for the first quarter of 2018, including consolidated statements of financial position and comprehensive income. While it is filed as a 6-K, the content is a comprehensive quarterly financial report containing substantive financial data and analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2018
2018-05-29 English
Immediate Report
Report Publication Announcement Classification · 98% confidence The document is a short filing (2258 characters) submitted to the Israel Securities Authority and the Tel Aviv Stock Exchange. The key sentence is: "Attached hereto is a report on*financial results for the quarter ended on March 31, 2018.*". This structure—a brief announcement stating that a financial report (in this case, quarterly results) is attached or published—fits the definition of a Report Publication Announcement (RPA). It is not the full financial report itself (which would likely be classified as IR or ER, depending on scope), but rather the notice of its publication. The presence of the attached PDF filename further supports this classification based on the 'MENU VS MEAL' rule.
2018-05-29 English
Other Report or Announcement
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is explicitly titled "Form 6-K" and is filed by a Foreign Private Issuer (XTL Biopharmaceuticals Ltd.) with the SEC. Form 6-K is used to report material events that occur between the required annual (20-F) and semi-annual reports. The content specifically announces the results of an "Extraordinary General Meeting of shareholders" held on May 22, 2018, detailing the approval of director reelections. This type of announcement regarding shareholder meeting outcomes, especially when filed on Form 6-K, aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA). While it relates to a general meeting, the core content is the *result* of the vote, not the proxy solicitation (PSI) or the general AGM presentation (AGM-R). Since DVA is the most specific category for reporting voting results, it is the correct classification.
2018-05-22 English
Other Report or Announcement
AGM Information Classification · 99% confidence The document is a filing submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The key phrase is: "Attached hereto is a report on *Extraordinary General Meeting Results.*". This explicitly states that the document is an announcement *about* the results of a general meeting, and it points to an attached PDF file containing the actual results. According to Rule 2 (The "MENU VS MEAL" RULE), a short document announcing the publication of a report is classified as a Report Publication Announcement (RPA). Although the content relates to an AGM/EGM result, the document itself is the announcement of that result, not the detailed results document. If the document contained the detailed results, it would be AGM-R (AGM Information) or potentially DVA (Declaration of Voting Results). Since it is an announcement stating the results are attached, RPA is the most appropriate classification based on the provided definitions and rules.
2018-05-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.